Huntington and Rare Diseases Unit, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.
Multiple Sclerosis Clinical and Research Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Neurol Sci. 2021 Nov;42(11):4583-4589. doi: 10.1007/s10072-021-05141-1. Epub 2021 Mar 2.
The Multiple Sclerosis Neuropsychological Questionnaire (MSNQ) is a brief questionnaire useful for screening patients with multiple sclerosis (MS) at risk for cognitive impairment. It includes a patient self-assessment (MSNQ-p) and a section for the caregiver (informant) (MSNQ-i). This study's aim was to validate the Italian version of MSNQ and to compare MSNQ scores with Symbol Digit Modality Test (SDMT), Beck Depression Inventory (BDI), and Expanded Disability Status Scale (EDSS) score, measuring cognitive skills, mood status, and physical disability respectively. We enrolled 122 MS patients (and related caregivers) at MS center of Tor Vergata University Hospital of Rome. The final study sample consisted of 122 patients with MS (90 relapsing-remitting, 24 secondary progressive, and 8 primary progressive). Our results highlighted that MSNQ has a unidimensional factor structure. Correlational analyses found a good correlation between both versions (MSNQ-p and MSNQ-i) of the questionnaire. Both MSNQ-p and MSNQ-i were correlated with clinical variables, specifically with cognitive impairment, mood disorder, and with disability. The Italian version of MSNQ is reliable and useful as screening tool to identify MS patients at high risk of cognitive impairment.
多发性硬化症神经心理学问卷 (MSNQ) 是一种简短的问卷，可用于筛查多发性硬化症 (MS) 患者认知障碍的风险。它包括患者自我评估 (MSNQ-p) 和照顾者 (知情人) 部分 (MSNQ-i)。本研究的目的是验证 MSNQ 的意大利语版本，并将 MSNQ 评分与符号数字模态测试 (SDMT)、贝克抑郁量表 (BDI) 和扩展残疾状态量表 (EDSS) 评分进行比较，分别衡量认知技能、情绪状态和身体残疾。我们在罗马 Tor Vergata 大学医院的多发性硬化症中心招募了 122 名 MS 患者 (及其相关照顾者)。最终的研究样本包括 122 名多发性硬化症患者 (90 名复发缓解型、24 名继发进展型和 8 名原发进展型)。我们的研究结果表明，MSNQ 具有单一维度的结构。相关分析发现问卷的两个版本 (MSNQ-p 和 MSNQ-i) 之间具有良好的相关性。MSNQ-p 和 MSNQ-i 均与临床变量相关，特别是与认知障碍、情绪障碍和残疾相关。MSNQ 的意大利语版本是可靠且有用的，可作为筛查工具，用于识别认知障碍风险较高的 MS 患者。
